StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Protagonist Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $175.16M, up 21.8% year over year. For fiscal 2025 it was $159.29M, up 15.3% from the year before. Over ten years it grew 29.7% a year on average. The highest annual figure on record is $159.29M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$159.29M+15.3%
FY2024Dec 31, 2024$138.13M+15.0%
FY2023Dec 31, 2023$120.16M-4.8%
FY2022Dec 31, 2022$126.22M+0.2%
FY2021Dec 31, 2021$126.01M+69.1%
FY2020Dec 31, 2020$74.51M+14.6%
FY2019Dec 31, 2019$65.00M+9.3%
FY2018Dec 31, 2018$59.50M+28.8%
FY2017Dec 31, 2017$46.18M+79.7%
FY2016Dec 31, 2016$25.71M+117.3%
FY2015Dec 31, 2015$11.83M+58.6%
FY2014Dec 31, 2014$7.46M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$42.06M+13.6%
Q1 FY2026Mar 31, 2026$46.74M+30.2%
Q4 FY2025Dec 31, 2025$46.36M+32.8%
Q3 FY2025Sep 30, 2025$40.00M+11.2%
Q2 FY2025Jun 30, 2025$37.04M+10.5%
Q1 FY2025Mar 31, 2025$35.89M+6.4%
Q4 FY2024Dec 31, 2024$34.90M+20.8%
Q3 FY2024Sep 30, 2024$35.97M+17.3%
Q2 FY2024Jun 30, 2024$33.52M+1.0%
Q1 FY2024Mar 31, 2024$33.73M+23.0%
Q4 FY2023Dec 31, 2023$28.90M-3.3%
Q3 FY2023Sep 30, 2023$30.66M+20.7%
Q2 FY2023Jun 30, 2023$33.18M-4.1%
Q1 FY2023Mar 31, 2023$27.42M-24.5%
Q4 FY2022Dec 31, 2022$29.88M-22.1%
Q3 FY2022Sep 30, 2022$25.40M-31.3%
Q2 FY2022Jun 30, 2022$34.61M+30.9%
Q1 FY2022Mar 31, 2022$36.32M+49.8%
Q4 FY2021Dec 31, 2021$38.37M+96.9%
Q3 FY2021Sep 30, 2021$36.96M+131.0%
Q2 FY2021Jun 30, 2021$26.43M+30.5%
Q1 FY2021Mar 31, 2021$24.25M+29.2%
Q4 FY2020Dec 31, 2020$19.49M+22.5%
Q3 FY2020Sep 30, 2020$16.00M-7.5%
Q2 FY2020Jun 30, 2020$20.26M+4.7%
Q1 FY2020Mar 31, 2020$18.77M+50.8%
Q4 FY2019Dec 31, 2019$15.91M+11.7%
Q3 FY2019Sep 30, 2019$17.29M+42.4%
Q2 FY2019Jun 30, 2019$19.36M+9.1%
Q1 FY2019Mar 31, 2019$12.44M-19.0%
Q4 FY2018Dec 31, 2018$14.25M+21.5%
Q3 FY2018Sep 30, 2018$12.15M+8.7%
Q2 FY2018Jun 30, 2018$17.74M+47.7%
Q1 FY2018Mar 31, 2018$15.37M+36.2%
Q4 FY2017Dec 31, 2017$11.72M+32.9%
Q3 FY2017Sep 30, 2017$11.17M+100.8%
Q2 FY2017Jun 30, 2017$12.01M–
Q1 FY2017Mar 31, 2017$11.28M–
Q4 FY2016Dec 31, 2016$8.82M–
Q3 FY2016Sep 30, 2016$5.56M–

More Protagonist Therapeutics figures

See a number that looks wrong?